NEW YORK – T2 Biosystems announced on Thursday that its preliminary 2019 fourth quarter revenues increased 67 percent year over year.
The Lexington, Massachusetts-based firm also said that John Sperzel has assumed the position of president and CEO of T2 Biosystems as of January 8, 2020. He replaces John McDonough in both roles.
Lastly, the company announced an exclusive distribution deal for its tests in Israel.